Market Cap 2.20B
Revenue (ttm) 781.37M
Net Income (ttm) -197.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -25.32%
Debt to Equity Ratio 1.57
Volume 2,870,300
Avg Vol 2,160,618
Day's Range N/A - N/A
Shares Out 125.52M
Stochastic %K 19%
Beta 0.85
Analysts Strong Sell
Price Target $43.50

Latest News on APLS

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 2:11 PM EDT - 25 days ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals


Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:06 PM EST - 7 weeks ago

Apellis Pharmaceuticals: A Mixed Bag